Mitchell Capital Management CO Bristol Myers Squibb CO Transaction History

Mitchell Capital Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$53.63 - $62.52 $2.46 Million - $2.87 Million	-45,897 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$59.17 - $69.31 $14,674 - $17,188	-248 Reduced 0.54%	45,897 $2.72 Million
Q2 2021 Aug 10, 2021	BUY	$61.91 - $67.42 $85,435 - $93,039	1,380 Added 3.08%	46,145 $3.08 Million
Q1 2021 Apr 29, 2021	BUY	$59.34 - $66.74 $216,294 - $243,267	3,645 Added 8.86%	44,765 $2.83 Million
Q4 2020 Feb 08, 2021	BUY	$57.74 - $65.43 $165,194 - $187,195	2,861 Added 7.48%	41,120 $2.55 Million
Q3 2020 Nov 10, 2020	BUY	$57.43 - $63.64 $61,277 - $67,903	1,067 Added 2.87%	38,259 $2.31 Million
Q2 2020 Jul 29, 2020	BUY	$54.82 - $64.09 $16,062 - $18,778	293 Added 0.79%	37,192 $2.19 Million
Q1 2020 May 06, 2020	BUY	$46.4 - $67.43 $379,459 - $551,442	8,178 Added 28.47%	36,899 $2.06 Million
Q4 2019 Feb 07, 2020	BUY	$49.21 - $64.19 $365,777 - $477,124	7,433 Added 34.92%	28,721 $1.84 Million
Q3 2019 Nov 07, 2019	BUY	$42.77 - $50.71 $910,487 - $1.08 Million	21,288 New	21,288 $1.08 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Mitchell Capital Management CO, based on Form 13F filings with the SEC.

Stay updated on Mitchell Capital Management CO with notifications on news.